DSIP · nasal spray · research use only
DSIP dosage, framed for sleep and circadian research.
DSIP — delta sleep-inducing peptide — is a nine-amino-acid neuropeptide studied around sleep architecture, stress response, and circadian regulation. Unlike the nootropic nasal peptides timed to a cognitive task, DSIP research anchors administration to the rest phase, which makes its timing question distinct even though its intranasal microgram framing looks familiar. This page lays out the reference amounts, the rest-phase timing logic, and Titan's metered-spray delivery as a laboratory reference — not a human protocol or medical advice.
A sleep-research nonapeptide
DSIP is a nine-amino-acid neuropeptide first isolated from work on sleep-related electrical activity, which is why its research clusters around sleep architecture, stress-axis regulation, and circadian questions rather than the cognition or recovery endpoints that drive the other nasal peptides. The functional class — not just the dose — is what sets a DSIP protocol apart.
DSIP sleep research →Microgram ranges in the literature
Sleep and stress-response research models DSIP in microgram amounts per administration, with study designs spanning a single-administration window depending on the endpoint. As with the other nasal peptides Titan stocks, it is referenced as an acute per-session amount rather than a milligram daily total. These figures are a laboratory reference, not a human protocol.
Read the research overview →Timed to the rest phase
This is what makes DSIP timing distinct: where a nootropic like Semax is administered before a cognitive task, sleep-architecture research anchors DSIP to the onset of the rest phase, since the endpoints being measured are sleep- and circadian-linked. The peptide is studied as short-acting, so the question is when relative to the rest window rather than how often across a day.
Why rest-phase timing matters →Metered spray — no reconstitution
Titan supplies DSIP as a ready-to-use metered nasal spray, so there is no bacteriostatic-water reconstitution step like a lyophilized injectable vial. Each actuation delivers a fixed volume, which is what lets a per-session microgram reference map onto a known per-spray amount. Storage and handling follow the nasal-spray shelf-life guidance rather than vial reconstitution math.
Nasal spray storage →Identity and concentration to confirm
For a nasal-spray format, the verification points are peptide identity and the labelled concentration per actuation. Titan's DSIP is characterised by mass-spec identity and HPLC purity against a ≥99% internal target on a lot-matched release sheet — so the microgram references on this page map onto a known concentration rather than an assumed one.
See the testing workflow →Research-use framing
DSIP in this format has no regulatory approval for human use. The microgram ranges and timing here are reproduced as a laboratory research reference for in-vitro and behavioural-modelling work — not instructions for human use. Titan supplies DSIP strictly as a research reagent, and nothing on this page is medical or dosing advice.
Research-use policy →The detail, in plain terms
The intranasal dosing reference, in one table.
The variables a sleep-research protocol weighs for intranasal DSIP — the peptide's functional class, the microgram unit convention, the rest-phase timing logic that distinguishes it from the nootropic peptides, and the metered-spray delivery that removes reconstitution. Reproduced as a reference, not a human protocol.
- Compound
- DSIP — delta sleep-inducing peptide, a nine-amino-acid neuropeptide.
- Unit convention
- Micrograms (mcg) per administration, not milligrams.
- Reference amount
- Acute per-session microgram amounts; study designs span a single-administration window.
- Timing
- Anchored to the onset of the rest phase rather than a cognitive task.
- Half-life
- Studied as a short-acting peptide; question is when, not how often.
- Format
- Ready-to-use metered nasal spray, $62.99 — no reconstitution.
Questions researchers ask
Before you order.
- What is the research dosage for intranasal DSIP?
- Sleep and stress-response research models DSIP in microgram amounts per administration, with study designs spanning a single-administration window depending on the endpoint. It is referenced as an acute per-session amount delivered nasally rather than a cumulative milligram daily total. These figures are a laboratory reference, not a human dosing protocol or medical advice.
- Why is DSIP timing different from a nootropic peptide?
- Nootropic nasal peptides like Semax are administered around a cognitive task, because that is what the endpoint measures. DSIP research is sleep- and circadian-linked, so administration is anchored to the onset of the rest phase instead. Same intranasal microgram framing, different timing logic — driven by the kind of endpoint each peptide is studied against.
- Does Titan's DSIP nasal spray need reconstitution?
- No. Titan supplies DSIP as a ready-to-use metered nasal spray, so there is no bacteriostatic-water reconstitution step like an injectable lyophilized vial. Each actuation delivers a fixed volume, which is what makes per-session microgram references practical to apply. Storage follows the nasal-spray shelf-life guidance rather than vial reconstitution math.
- What should a DSIP COA confirm?
- For a nasal-spray peptide the verification points are identity and concentration: mass-spec confirmation that the nonapeptide sequence is correct and HPLC purity against a defined target, on a lot-matched release sheet so the figure applies to the unit you receive. Titan characterises DSIP to a ≥99% internal purity target. See the how-to-verify-peptide-quality-COA guide for how to read those numbers.
- Is DSIP approved for human use in this format?
- No. Titan's DSIP nasal spray has no regulatory approval for human use. Titan Peptide Lab supplies it strictly as a research-use-only reagent for in-vitro and behavioural-modelling laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use.